Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?

Executive Summary

Success of enhanced communications in particular made one stakeholder wonder whether FDA could use it with non-breakthrough applications.

Advertisement

Related Content

Unhappy With GDUFA II? Note It For GDUFA III, FDA Says
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed
CDRH's Expedited Access Pathway: 17 Devices And Counting
Biosimilars Program Could 'Explode,' Woodcock Warns Congress
FDA’s Woodcock Cautions Efforts To 'Legislate A New Generation Of Biomarkers'
Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting
FDA’s Breakthrough Products: Could Patients Drive The Designations?
Biomarkers For Rare Diseases Get Scaled-Back Plea In New White Paper

Topics

Advertisement
UsernamePublicRestriction

Register

PS118988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel